Can a Prebiotic Formulation Reduce Frailty Levels in Older People?

Theou, Olga; Jayanama, Kulapong; Fernández-Garrido, Julio; Buigues, Cristina; Pruimboom, Leo; Hoogland, A. J.; Navarro-Martínez, Rut; Rockwood, Kenneth; Cauli, Omar

doi:10.14283/jfa.2018.39

Cited by 29 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, the intervention group experienced significant improvements in handgrip strength and self-reported feeling of exhaustion (78). Subsequently Theou et al conducted secondary analysis by using a similar intervention (inulin+FOS versus placebo) and showed improvements in physical function, frailty degree, nutritional status and quality of life following a 12-week intervention in frail elderly (115).…”

Section: Human Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure

et al. 2021

View full text Add to dashboard Cite

Sarcopenia represents a major health burden in industrialized country by reducing substantially the quality of life. Indeed, it is characterized by a progressive and generalized loss of muscle mass and function, leading to an increased risk of adverse outcomes and hospitalizations. Several factors are involved in the pathogenesis of sarcopenia, such as aging, inflammation, mitochondrial dysfunction, and insulin resistance. Recently, it has been reported that more than one third of inflammatory bowel disease (IBD) patients suffered from sarcopenia. Notably, the role of gut microbiota (GM) in developing muscle failure in IBD patient is a matter of increasing interest. It has been hypothesized that gut dysbiosis, that typically characterizes IBD, might alter the immune response and host metabolism, promoting a low-grade inflammation status able to up-regulate several molecular pathways related to sarcopenia. Therefore, we aim to describe the basis of IBD-related sarcopenia and provide the rationale for new potential therapeutic targets that may regulate the gut-muscle axis in IBD patients.

show abstract

Section: Human Studiesmentioning

confidence: 99%

“…Subsequently Theou et al. conducted secondary analysis by using a similar intervention (inulin+FOS versus placebo) and showed improvements in physical function, frailty degree, nutritional status and quality of life following a 12-week intervention in frail elderly ( 115 ).…”

Section: Studies Exploring Ibd and Sarcopeniamentioning

confidence: 99%

Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The differences in dietary intake, medication use, and clinical status between the subgroups had an effect on modulating the gut microbiota ( 52 , 57 , 58 ) and may have acted as confounding variables that contributed to the associations observed between health and gut microbiota composition in the study ( 31 ). Other studies also suggest that physical frailty is inversely related to gut microbiota biodiversity and the relative abundance of a number of key taxa ( 31 , 50 , 52 , 59 – 63 ). However, even if these studies reduced or excluded confounding factors, it is not possible in observational study designs to establish a cause–effect relationship between a specific gut microbiota composition or taxa and healthy ageing or longevity.…”

Section: Ageing and The Gut Microbiota—insights From Human Studiesmentioning

confidence: 98%

Targeting the Gut Microbiota to Improve Dietary Protein Efficacy to Mitigate Sarcopenia

2021

View full text Add to dashboard Cite

Sarcopenia is characterised by the presence of diminished skeletal muscle mass and strength. It is relatively common in older adults as ageing is associated with anabolic resistance (a blunted muscle protein synthesis response to dietary protein consumption and resistance exercise). Therefore, interventions to counteract anabolic resistance may benefit sarcopenia prevention and are of utmost importance in the present ageing population. There is growing speculation that the gut microbiota may contribute to sarcopenia, as ageing is also associated with [1) dysbiosis, whereby the gut microbiota becomes less diverse, lacking in healthy butyrate-producing microorganisms and higher in pathogenic bacteria, and [2) loss of epithelial tight junction integrity in the lining of the gut, leading to increased gut permeability and higher metabolic endotoxemia. Animal data suggest that both elements may impact muscle physiology, but human data corroborating the causality of the association between gut microbiota and muscle mass and strength are lacking. Mechanisms wherein the gut microbiota may alter anabolic resistance include an attenuation of gut-derived low-grade inflammation and/or the increased digestibility of protein-containing foods and consequent higher aminoacidemia, both in favour of muscle protein synthesis. This review focuses on the putative links between the gut microbiota and skeletal muscle in the context of sarcopenia. We also address the issue of plant protein digestibility because plant proteins are increasingly important from an environmental sustainability perspective, yet they are less efficient at stimulating muscle protein synthesis than animal proteins.

show abstract

“…In a randomized controlled trial (RCT) exploring the effects of a mixture of inulin and FOS ( versus placebo) in ambulatory elderly residing in nursing homes, the intervention group experienced significant improvements in handgrip strength and self-reported feeling of exhaustion after 13 weeks of supplementation, while the overall rate of frailty remained unchanged. 68 By using a similar intervention (inulin + FOS versus placebo over a 13-week period), Theou et al 69 demonstrated a modest reduction in a 62-item frailty index in older individuals receiving the prebiotic mixture. Improvements in physical function, frailty degree, nutritional status and quality of life were also shown following a 12-week intervention with an oral nutritional supplementation (FOS and inulin, protein, Ca, Vitamin D) plus physical exercise in frail elderly ( versus baseline, no control group); nevertheless, it was not possible to disentangle the contributions of the individual components of this multimodal intervention to the observed favourable changes.…”

Section: Prebiotics and Probiotics For The Modulation Of Gut Microbiome And Musculoskeletal Health In Humans (Adults)mentioning

confidence: 99%

Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases

Papageorgiou

2021

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Despite major progress in the understanding of the pathophysiology and therapeutic options for common ageing-related musculoskeletal conditions (i.e. osteoporosis and associated fractures, sarcopenia and osteoarthritis), there is still a considerable proportion of patients who respond sub optimally to available treatments or experience adverse effects. Emerging microbiome research suggests that perturbations in microbial composition, functional and metabolic capacity (i.e. dysbiosis) are associated with intestinal and extra-intestinal disorders including musculoskeletal diseases. Besides its contributions to disease pathogenesis, the role of the microbiome is further extended to shaping individuals’ responses to disease therapeutics (i.e. pharmacomicrobiomics). In this review, we focus on the reciprocal interactions between the microbiome and therapeutics for osteoporosis, sarcopenia and osteoarthritis. Specifically, we identify the effects of therapeutics on microbiome’s configurations, functions and metabolic output, intestinal integrity and immune function, but also the effects of the microbiome on the metabolism of these therapeutics, which in turn, may influence their bioavailability, efficacy and side-effect profile contributing to variable treatment responses in clinical practice. We further discuss emerging strategies for microbiota manipulation as preventive or therapeutic (alone or complementary to available treatments) approaches for improving outcomes of musculoskeletal health and disease.

show abstract

Can a Prebiotic Formulation Reduce Frailty Levels in Older People?

Cited by 29 publications

References 28 publications

Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure

Inflammatory Bowel Diseases and Sarcopenia: The Role of Inflammation and Gut Microbiota in the Development of Muscle Failure

Targeting the Gut Microbiota to Improve Dietary Protein Efficacy to Mitigate Sarcopenia

Interactions of the microbiome with pharmacological and non-pharmacological approaches for the management of ageing-related musculoskeletal diseases

Contact Info

Product

Resources

About